MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diagnoses in the U.S. annually CHICAGO, April 16, 2026 ( …